ESPR
Esperion Therapeutics, Inc.NASDAQHealthcare$2.61+0.00%ClosedMarket Cap: $542.6M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
-2.00
P/S
1.32
EV/EBITDA
14.50
DCF Value
$-62.04
FCF Yield
-2.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
64.4%
Operating Margin
15.0%
Net Margin
-5.6%
ROE
5.6%
ROA
-4.9%
ROIC
23.7%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $168.4M | 83.5% | $85.2M | $61.8M | $0.22 | — |
| FY 2025 | $403.1M | 67.9% | $60.3M | $-22.7M | $-0.11 | — |
| Q3 2025 | $87.3M | 36.5% | $-10.0M | $-31.3M | $-0.16 | — |
| Q2 2025 | $82.4M | 65.4% | $7.1M | $-12.7M | $-0.02 | — |
| Q1 2025 | $65.0M | 51.5% | $-22.1M | $-40.5M | $-0.21 | — |
| Q4 2024 | $69.1M | 62.9% | $-4.4M | $-21.3M | $-0.11 | — |
| FY 2024 | $332.3M | 79.4% | $54.4M | $-51.7M | $-0.28 | — |
| Q3 2024 | $51.6M | 66.5% | $-16.0M | $-29.5M | $-0.15 | — |
| Q2 2024 | $73.8M | 78.9% | $2.6M | $-61.9M | $-0.33 | — |
| Q1 2024 | $137.7M | 92.7% | $72.3M | $61.0M | $0.34 | — |
| Q4 2023 | $32.3M | 64.5% | $-42.4M | $-56.3M | $-0.50 | — |
| FY 2023 | $116.3M | 62.8% | $-155.6M | $-209.2M | $-2.03 | — |